Profil bibliographique

Andrea Stefek

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

101Publications signalées

1996Citations signalées

2Affiliations récentes

Les institutions déclarées

Die Johanniter Hochschule Magdeburg-Stendal

Les domaines associés

HER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesLung Cancer Treatments and MutationsAdvanced Breast Cancer TherapiesPARP inhibition in cancer therapy

Les publications récentes

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S6 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S4 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S5 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S3 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S7 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

Thomas E. Mürdter, Werner Schroth, Matthew P. Goetz, Roman Tremmel et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

"Supplementary Table S6 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S1 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S3 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.